

Title (en)

SOLID FORMS OF ANTI-EGFR-ANTIBODIES

Title (de)

FESTE FORMEN VON ANTI-EGFR-ANTIKÖRPERN

Title (fr)

FORMES SOLIDES D'ANTICORPS ANTI-EGFR

Publication

EP 1686961 A1 20060809 (DE)

Application

EP 04797849 A 20041112

Priority

- EP 2004012837 W 20041112
- DE 10355904 A 20031129

Abstract (en)

[origin: WO2005051355A1] The invention relates to solid forms of antibodies against the EGF receptor, especially precipitates and crystals of monoclonal antibodies against the EGF receptor, especially preferably Mab C225 (Cetuximab) and Mab h425 (EMD 72000), that create biologically active antibody proteins by dissolution or suspension in an aqueous medium. Said proteins can be obtained by precipitation of the antibody dissolved or suspended in the aqueous medium and/or one of the variants or fragments thereof by means of a precipitation reagent. The invention also relates to pharmaceutical preparations containing at least one solid form of the cited antibody in a precipitated non-crystalline form, a precipitated crystalline form or a soluble or suspended form, and optionally carrier and/or auxiliary substances and/or other pharmaceutical active ingredients, and to a method for producing inventive solid forms of anti-EGFR-antibodies.

IPC 8 full level

A61K 9/14 (2006.01); **A61K 39/395** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP KR US)

A61K 9/14 (2013.01 - KR); **A61K 39/395** (2013.01 - KR); **A61K 39/39591** (2013.01 - EP US); **A61P 35/00** (2017.12 - EP);
C07K 16/2863 (2013.01 - EP US); **C30B 7/00** (2013.01 - EP US); **A61K 9/143** (2013.01 - EP US); **A61K 9/145** (2013.01 - EP US);
A61K 2039/505 (2013.01 - EP US); **C07K 2299/00** (2013.01 - EP US); **C07K 2317/24** (2013.01 - EP US)

Citation (search report)

See references of WO 2005051355A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2005051355 A1 20050609; AR 046677 A1 20051214; AU 2004292742 A1 20050609; AU 2004292742 B2 20110825;
AU 2004292742 B9 20111124; BR PI0416968 A 20070221; CA 2547446 A1 20050609; CA 2547446 C 20130514; CN 1886118 A 20061227;
CO 5690537 A2 20061031; DE 10355904 A1 20050630; EC SP066681 A 20061025; EP 1686961 A1 20060809; EP 1974723 A2 20081001;
EP 1974723 A3 20100609; IL 175935 A0 20061005; IL 175935 A 20131031; KR 20060111539 A 20061027; KR 20120093406 A 20120822;
MX PA06005968 A 20060706; MY 148228 A 20130329; NZ 548210 A 20101029; PE 20050667 A1 20050927; RU 2006123005 A 20080120;
RU 2397755 C2 20100827; TW 200530268 A 20050916; TW I350291 B 20111011; UA 84893 C2 20081210; US 2007122411 A1 20070531;
US 7960516 B2 20110614; ZA 200605348 B 20070425

DOCDB simple family (application)

EP 2004012837 W 20041112; AR P040104385 A 20041126; AU 2004292742 A 20041112; BR PI0416968 A 20041112;
CA 2547446 A 20041112; CN 200480034587 A 20041112; CO 06050507 A 20060525; DE 10355904 A 20031129; EC SP066681 A 20060628;
EP 04797849 A 20041112; EP 08011237 A 20041112; IL 17593506 A 20060525; KR 20067010456 A 20060529; KR 20127017106 A 20041112;
MX PA06005968 A 20041112; MY PI20044872 A 20041124; NZ 54821004 A 20041112; PE 2004001170 A 20041126;
RU 2006123005 A 20041112; TW 93136625 A 20041126; UA A200607231 A 20041112; US 58056304 A 20041112; ZA 200605348 A 20060628